Long-Term Outcomes for Patients with Multiple Endocrine Neoplasia Type 1 and Duodenopancreatic Neuroendocrine Neoplasms

Overview

Journal Ann Surg Oncol

Publisher Springer

Specialty Oncology

Date 2022 Aug 13

PMID 35963905

Authors

Jason B Liu

Jinman Cai

Mashaal Dhir

Alessandro Paniccia

Amer H Zureikat

Kimberly M Ramonell

Kelly L McCoy

Sally E Carty

Linwah Yip

Affiliations

Soon will be listed here.

Abstract

Background: Liver metastasis from duodenopancreatic neuroendocrine neoplasms (DP-NENs) is a major cause of mortality in multiple endocrine neoplasia type 1 (MEN1) patients, yet much of their natural history is unknown.

Methods: This longitudinal, retrospective cohort study analyzed all MEN1 patients with imageable functional (F) and nonfunctional (NF) DP-NENs (1990-2021) for liver metastasis-free survival (LMFS) and overall survival (OS).

Results: Of 138 patients, 85 (61.6%) had imageable DP-NENs (28 F, 57 NF), and the mean largest tumor size was 1.8 ± 1.4 cm. Multifocality was present in 32 patients (37.7%). Surgery was performed for 49 patients (57.7%). During an 11-year median follow-up period (IQR, 6-17 years), 23 (27.1%) of the patients had liver metastasis, and 19 (22.4%) patients died. Death was attributed to liver metastasis in 60% of cases. The patients with F-DP-NENs versus NF-DP-NENs more often had liver metastasis (46.4% vs. 15.8%; p = 0.002) but had similar 10-year LMFS (80.9 vs. 87.0%; p = 0.44) and OS (82.7 vs. 94.3%; p = 0.69). The patients with NF-DP-NENs had surgery when their tumors were larger (p < 0.001). Tumor size was not associated with liver metastasis (p = 0.89). The average growth rate was 0.04 cm/year (SE, 0.02 cm/year; p = 0.01) during active surveillance for NF-DP-NENs (n = 38). Liver metastasis developed in four patients with tumors smaller than 2 cm. The risk of liver metastasis was independent of surgery (hazard ratio [HR], 0.78; 95% confidence interval [CI], 0.21-2.93; p = 0.72) and death (HR, 0.51; 95% CI, 0.08-3.06; p = 0.46).

Conclusions: Although the observed outcomes in this study were better than historical data, small NF-DP-NENs still developed liver metastasis and liver metastasis remains a major cause of death. These results suggest that size as a sole criterion for surgery may be insufficient to predict tumor behavior.

References

Al-Salameh A, Cadiot G, Calender A, Goudet P, Chanson P . Clinical aspects of multiple endocrine neoplasia type 1. Nat Rev Endocrinol. 2021; 17(4):207-224. DOI: 10.1038/s41574-021-00468-3. View

Yates C, Newey P, Thakker R . Challenges and controversies in management of pancreatic neuroendocrine tumours in patients with MEN1. Lancet Diabetes Endocrinol. 2015; 3(11):895-905. DOI: 10.1016/S2213-8587(15)00043-1. View

Goudet P, Murat A, Binquet C, Cardot-Bauters C, Costa A, Ruszniewski P . Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg. 2009; 34(2):249-55. DOI: 10.1007/s00268-009-0290-1. View

Niederle B, Selberherr A, Bartsch D, Brandi M, Doherty G, Falconi M . Multiple Endocrine Neoplasia Type 1 and the Pancreas: Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome - An International Consensus Statement. Neuroendocrinology. 2020; 111(7):609-630. DOI: 10.1159/000511791. View

Triponez F, Sadowski S, Pattou F, Cardot-Bauters C, Mirallie E, Le Bras M . Long-term Follow-up of MEN1 Patients Who Do Not Have Initial Surgery for Small ≤2 cm Nonfunctioning Pancreatic Neuroendocrine Tumors, an AFCE and GTE Study: Association Francophone de Chirurgie Endocrinienne & Groupe d'Etude des Tumeurs Endocrines. Ann Surg. 2017; 268(1):158-164. PMC: 6012055. DOI: 10.1097/SLA.0000000000002191. View

Norton J, Alexander H, Fraker D, Venzon D, Gibril F, Jensen R . Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg. 2001; 234(4):495-505; discussion 505-6. PMC: 1422073. DOI: 10.1097/00000658-200110000-00009. View

van Leeuwaarde R, Pieterman C, Bleiker E, Dekkers O, van der Horst-Schrivers A, Hermus A . High Fear of Disease Occurrence Is Associated With Low Quality of Life in Patients With Multiple Endocrine Neoplasia Type 1: Results From the Dutch MEN1 Study Group. J Clin Endocrinol Metab. 2018; 103(6):2354-2361. DOI: 10.1210/jc.2018-00259. View

van Leeuwaarde R, Pieterman C, May A, Dekkers O, van der Horst-Schrivers A, Hermus A . Health-Related Quality of Life in Patients with Multiple Endocrine Neoplasia Type 1. Neuroendocrinology. 2020; 111(3):288-296. DOI: 10.1159/000508374. View

Sadowski S, Pieterman C, Perrier N, Triponez F, Valk G . Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature. Endocr Relat Cancer. 2020; 27(6):R145-R161. PMC: 7304521. DOI: 10.1530/ERC-19-0372. View

10.

Vinault S, Mariet A, Le Bras M, Mirallie E, Cardot-Bauters C, Pattou F . Metastatic Potential and Survival of Duodenal and Pancreatic Tumors in Multiple Endocrine Neoplasia Type 1: A GTE and AFCE Cohort Study (Groupe d'étude des Tumeurs Endocrines and Association Francophone de Chirurgie Endocrinienne). Ann Surg. 2018; 272(6):1094-1101. DOI: 10.1097/SLA.0000000000003162. View

11.

Nell S, Verkooijen H, Pieterman C, de Herder W, Hermus A, Dekkers O . Management of MEN1 Related Nonfunctioning Pancreatic NETs: A Shifting Paradigm: Results From the DutchMEN1 Study Group. Ann Surg. 2017; 267(6):1155-1160. DOI: 10.1097/SLA.0000000000002183. View

12.

Lowney J, Frisella M, Lairmore T, Doherty G . Pancreatic islet cell tumor metastasis in multiple endocrine neoplasia type 1: correlation with primary tumor size. Surgery. 1998; 124(6):1043-8, discussion 1048-9. DOI: 10.1067/msy.1998.92561. View

13.

Kouvaraki M, Shapiro S, Cote G, Lee J, Yao J, Waguespack S . Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg. 2006; 30(5):643-53. DOI: 10.1007/s00268-006-0360-y. View

14.

Donegan D, Singh Ospina N, Rodriguez-Gutierrez R, Al-Hilli Z, Thompson G, Clarke B . Long-term outcomes in patients with multiple endocrine neoplasia type 1 and pancreaticoduodenal neuroendocrine tumours. Clin Endocrinol (Oxf). 2016; 86(2):199-206. DOI: 10.1111/cen.13264. View

15.

Sakurai A, Suzuki S, Kosugi S, Okamoto T, Uchino S, Miya A . Multiple endocrine neoplasia type 1 in Japan: establishment and analysis of a multicentre database. Clin Endocrinol (Oxf). 2011; 76(4):533-9. DOI: 10.1111/j.1365-2265.2011.04227.x. View

16.

Bartsch D, Fendrich V, Langer P, Celik I, Kann P, Rothmund M . Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg. 2005; 242(6):757-64, discussion 764-6. PMC: 1409888. DOI: 10.1097/01.sla.0000189549.51913.d8. View

17.

Fahrmann J, Wasylishen A, Pieterman C, Irajizad E, Vykoukal J, Murage E . A Blood-based Polyamine Signature Associated With MEN1 Duodenopancreatic Neuroendocrine Tumor Progression. J Clin Endocrinol Metab. 2021; 106(12):e4969-e4980. PMC: 8864750. DOI: 10.1210/clinem/dgab554. View

18.

Faggiano A, Modica R, Lo Calzo F, Camera L, Napolitano V, Altieri B . Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters. J Clin Endocrinol Metab. 2019; 105(1). DOI: 10.1210/clinem/dgz007. View

19.

Cejas P, Drier Y, Dreijerink K, Brosens L, Deshpande V, Epstein C . Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors. Nat Med. 2019; 25(8):1260-1265. PMC: 6919319. DOI: 10.1038/s41591-019-0493-4. View

20.

Christakis I, Qiu W, Hyde S, Cote G, Grubbs E, Perrier N . Genotype-phenotype pancreatic neuroendocrine tumor relationship in multiple endocrine neoplasia type 1 patients: A 23-year experience at a single institution. Surgery. 2017; 163(1):212-217. DOI: 10.1016/j.surg.2017.04.044. View